Wave Life Sciences (WVE)
NASDAQ:WVE
WVE Stock Chart & Stats
$11.63
-$0.07(-0.54%)
At close: 4:00 PM EST
$11.63
-$0.07(-0.54%)
Day’s Range― - ―
52-Week Range$5.28 - $21.73
Previous CloseN/A
Volume104.35K
Average Volume (3M)2.45M
Market Cap
$2.19B
Enterprise Value$1.61B
Total Cash (Recent Filing)$602.07M
Total Debt (Recent Filing)$17.77M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 07, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding188,254,960
10 Day Avg. Volume2,677,233
30 Day Avg. Volume2,453,816
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue37.57
Enterprise Value/Gross Profit44.46
Enterprise Value/Ebitda-8.00
Forecast
1Y Price Target
$33.73Price Target Upside190.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$37.24M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEvidence of a clear dose response with reductions in visceral fat while preserving or increasing lean mass would demonstrate a differentiated obesity treatment effect versus current therapies and could attract strategic interest.
Platform And ManufacturingA chemistry-led RNA platform plus manufacturing costs that are comparable to peers supports expansion into multiple genetic targets and improves the prospects for commercially viable programs.
Regulatory PathwayRegaining full rights to the RNA editing program and engaging the regulator on biomarker-based accelerated approval could streamline development and reduce regulatory risk for the AATD program.
Bears Say
Durability And Dosing RationaleMuting of weight‑loss momentum, lack of durable visceral‑fat reduction, or unexpected safety issues could undermine the infrequent‑dosing rationale and produce meaningful downside for investor expectations.
Patient Population TranslationEarly study participants had lower baseline body mass than the intended population, creating the risk that dose-dependent benefits may be smaller when tested in higher‑BMI patients.
Regulatory UncertaintyUsing mid-study weight loss as a proxy for regulatory efficacy increases pressure on interim results and raises the chance of regulatory uncertainty if efficacy thresholds are not clearly met.
Wave Life Sciences News
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $5.28 and its highest was $21.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is $2.19B.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is May 07, 2026 which is in 42 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Feb 26, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.026.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.32.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 188,254,960 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went up 5.64%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in WVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.73 (190.03% Upside)
$33.73 (190.03% Upside)
Blogger Sentiment
Bullish
WVE Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $258.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.49%
12-Months-Change
Fundamentals
Return on Equity
-84.99%
Trailing 12-Months
Asset Growth
81.29%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
WVE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical progress across multiple high-value programs (notably differentiated Phase I body-composition signals for WVE-007, compelling RNA editing results for WVE-006, and advancement of WVE-008), strong platform differentiation (SpiNA chemistry), concrete partnership milestones and a cash runway into Q3 2028. These positives are tempered by a large, one-time-driven revenue decline (Takeda termination), rising operating expenses and widening net losses, plus normal early-stage and competitive/regulatory uncertainties. On balance, the clinical and platform progress combined with an adequate cash runway and partnership upside outweigh near-term financial headwinds, but the business remains execution- and data-dependent over the next 12–18 months.View all WVE earnings summariesWVE Stock 12 Month Forecast
Average Price Target
$33.73
▲(190.03% Upside)
Technical Analysis
Precigen
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Rapport Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---